<?xml version='1.0' encoding='utf-8'?>
<document id="28967981"><sentence text="Pharmacokinetic Drug Interactions of Apatinib With Rifampin and Itraconazole."><entity charOffset="51-59" id="DDI-PubMed.28967981.s1.e0" text="Rifampin" /><entity charOffset="64-76" id="DDI-PubMed.28967981.s1.e1" text="Itraconazole" /><pair ddi="false" e1="DDI-PubMed.28967981.s1.e0" e2="DDI-PubMed.28967981.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28967981.s1.e0" e2="DDI-PubMed.28967981.s1.e1" /></sentence><sentence text="Apatinib is a small-molecule tyrosine kinase inhibitor that has been approved for the treatment of patients with advanced-stage gastric cancer or gastroesophageal junction cancer who have progressed or recurred after at least 2 kinds of systemic chemotherapy"><entity charOffset="0-8" id="DDI-PubMed.28967981.s2.e0" text="Apatinib" /><entity charOffset="29-37" id="DDI-PubMed.28967981.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.28967981.s2.e0" e2="DDI-PubMed.28967981.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28967981.s2.e0" e2="DDI-PubMed.28967981.s2.e1" /></sentence><sentence text=" In vitro data indicate that cytochrome P450 (CYP) 3A4 is the primary CYP isoenzyme involved in the metabolism of apatinib"><entity charOffset="114-122" id="DDI-PubMed.28967981.s3.e0" text="apatinib" /></sentence><sentence text=" Pharmacokinetic drug-drug interactions of apatinib and (1) a CYP3A4 inducer (rifampin) or (2) a CYP3A inhibitor (itraconazole) were clinically evaluated in healthy volunteers"><entity charOffset="43-51" id="DDI-PubMed.28967981.s4.e0" text="apatinib" /><entity charOffset="78-86" id="DDI-PubMed.28967981.s4.e1" text="rifampin" /><entity charOffset="114-126" id="DDI-PubMed.28967981.s4.e2" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.28967981.s4.e0" e2="DDI-PubMed.28967981.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28967981.s4.e0" e2="DDI-PubMed.28967981.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28967981.s4.e0" e2="DDI-PubMed.28967981.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28967981.s4.e1" e2="DDI-PubMed.28967981.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28967981.s4.e1" e2="DDI-PubMed.28967981.s4.e2" /></sentence><sentence text=" Compared with the single administration of apatinib, its coadministration with rifampin resulted in a 5"><entity charOffset="44-52" id="DDI-PubMed.28967981.s5.e0" text="apatinib" /><entity charOffset="80-88" id="DDI-PubMed.28967981.s5.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.28967981.s5.e0" e2="DDI-PubMed.28967981.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28967981.s5.e0" e2="DDI-PubMed.28967981.s5.e1" /></sentence><sentence text="6-fold plasma clearance (CL/F) and 83% decrease in plasma AUC0-t of apatinib"><entity charOffset="68-76" id="DDI-PubMed.28967981.s6.e0" text="apatinib" /></sentence><sentence text=" By contrast, coadministration with itraconazole reduced the CL/F of apatinib by 40% and increased its AUC0-t by 75%"><entity charOffset="36-48" id="DDI-PubMed.28967981.s7.e0" text="itraconazole" /><entity charOffset="69-77" id="DDI-PubMed.28967981.s7.e1" text="apatinib" /><pair ddi="false" e1="DDI-PubMed.28967981.s7.e0" e2="DDI-PubMed.28967981.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28967981.s7.e0" e2="DDI-PubMed.28967981.s7.e1" /></sentence><sentence text=" In summary, a strong CYP3A4 inducer (rifampin) had a strong effect (&gt;5-fold) on the clinical pharmacokinetics of apatinib, whereas a strong CYP3A inhibitor (itraconazole 100 mg once a day) had a weak effect (1"><entity charOffset="38-46" id="DDI-PubMed.28967981.s8.e0" text="rifampin" /><entity charOffset="114-122" id="DDI-PubMed.28967981.s8.e1" text="apatinib" /><entity charOffset="158-170" id="DDI-PubMed.28967981.s8.e2" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.28967981.s8.e0" e2="DDI-PubMed.28967981.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28967981.s8.e0" e2="DDI-PubMed.28967981.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28967981.s8.e0" e2="DDI-PubMed.28967981.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28967981.s8.e1" e2="DDI-PubMed.28967981.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28967981.s8.e1" e2="DDI-PubMed.28967981.s8.e2" /></sentence><sentence text="25- to 2-fold)" /><sentence text=" Whether these effects are of clinical significance needs further research and information about the exposure-safety and exposure-efficacy relationship of apatinib"><entity charOffset="155-163" id="DDI-PubMed.28967981.s10.e0" text="apatinib" /></sentence><sentence text="" /></document>